Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology

Citation
M. Egeblad et al., Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology, INT J CANC, 94(2), 2001, pp. 185-191
Citations number
35
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF CANCER
ISSN journal
00207136 → ACNP
Volume
94
Issue
2
Year of publication
2001
Pages
185 - 191
Database
ISI
SICI code
0020-7136(20011015)94:2<185:TEREES>2.0.ZU;2-#
Abstract
Shedding of the extracellular domain of the ErbB2 tyrosine kinase receptor and expression of the remaining NH2-terminally truncated ErbB2 correlates w ith lymph node metastases and adverse outcome in human breast cancer. To st udy the possible signaling from such a truncated receptor, MCF-7 human brea st cancer cells expressing NH2-terminally truncated ErbB2 (Delta NErbB2) we re compared with cells overexpressing wild-type ErbB2. Expression of Delta NErbB2 in MCF-7 cells resulted in sustained activation of extracellular sig nal-regulated kinases (ERK) 1/2, extensive loss of the epithelial morpholog y, appearance of vesicles and long protrusions as well as pronounced scatte ring of the cells. Similar alterations were observed upon ErbB2 overexpress ion but at much lower levels. Employing cell clones with inducible expressi on of Delta NErbB2, it was revealed that the morphological changes were ful ly reversible and depended on continuous expression of Delta NErbB2 but not on the activation of the ERK 1/2 pathway. Interestingly, the expression of Delta NErbB2 resulted also in the increased expression and phosphorylation of ErbB 1 as well as in the prolonged ligand-induced activation of the Erb B 1 signaling pathway. In conclusion, constitutive signaling upon expressio n of the truncated ErbB2 receptor in human breast cancer cells promotes mor phological changes indicative of a more motile and aggressive phenotype. (C ) 2001 Wiley-Liss, Inc.